Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIPAC-003: Eftilagimod alpha plus paclitaxel in HER2-negative/low metastatic breast cancer
2024-511023-34-00Phase 3Completed
- Sponsor
- Immutep Limited
- Start
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of eftilagimod alpha in breast cancer and triple-negative breast cancer (TNBC) (3 arms), sponsored by Immutep Limited. Primary endpoints: Dose optimization lead-in safety and tolerability, Dose optimization lead-in clinical safety parameters and 2 more. Started Jun 2024; status: completed.
02
Drugs
eftilagimod alpha
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2024-511023-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511023-34-00.